Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 3 4Phase 1 4Phase 2/3 2Phase 1/2 2

Status

Completed 6Recruiting 5Active not recruiting 4

Sponsor Class

NIH 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Plasma cell 1

Conditions

Burkitt Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Down Syndrome 1

Interventions

Carboplatin 108Cisplatin 98Paclitaxel 79pembrolizumab 70Gemcitabine 60Pemetrexed 49Cyclophosphamide 48Dexamethasone 47Docetaxel 46durvalumab 44Capecitabine 44Radiotherapy 42Doxorubicin 40Lenalidomide 38Specimen Handling 37Nivolumab 37Oxaliplatin 35Rituximab 34Magnetic Resonance Spectroscopy 33Fluorouracil 33Etoposide 32Bevacizumab 32Vincristine 30atezolizumab 29Radiation 28Leucovorin 28Bortezomib 26Prednisone 23Letrozole 23Fulvestrant 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Active not recruiting × prednylidene × Clear all
NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT02883049 2026-05-04

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

National Cancer Institute (NCI)

Phase 3 Active not recruiting
5,949 enrolled 28 charts
Lymphoid

Burkitt Lymphoma

NCT02003222 2026-05-01

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
488 enrolled 13 charts 1 FDA
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00602641 2026-04-29

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
306 enrolled 12 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡